ALCYONE — lighting the way for quadruplet therapy of NDMM
ALCYONE — lighting the way for quadruplet therapy of NDMM
Related Articles
FDA approves selpercatinib for medullary thyroid cancer
On September 27, 2024, the FDA granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for RET fusion-positive medullary thyroid cancer.
FDA approves Sarclisa with bortezomib, lenalidomide, and dexamethasone
FDA approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with diagnosed multiple myeloma
FDA approves amivantamab-vmjw with carboplatin and pemetrexed
On September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for non-small cell lung cancer.
FDA approves Kisqali and Kisqali Femara Co-Pack
On September 17, 2024, the FDA approved ribociclib (Kisqali, Novartis) and ribociclib and letrozole co-pack (Kisqali Femara Co-Pack, Novartis).
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
FDA approves atezolizumab and hyaluronidase-tqjs
On September 12, 2024, the FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection.
The age of foundation models
Nature Reviews Clinical Oncology – The development of clinically relevant artificial intelligence (AI) models has traditionally required access to extensive labelled datasets, which inevitably…